-
Risk, protective, and biomarkers of dementia in Indigenous peoples: A systematic review Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-25 Huong X. T. Nguyen, Kate Bradley, Bridgette J. McNamara, Rosie Watson, Roslyn Malay, Dina LoGiudice
Dementia is an emergent health priority for Indigenous peoples worldwide, yet little is known about disease drivers and protective factors.
-
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-23 Olivia Wagemann, Yan Li, Jason Hassenstab, Andrew J. Aschenbrenner, Nicole S. McKay, Brian A. Gordon, Tammie L. S. Benzinger, Chengjie Xiong, Carlos Cruchaga, Alan E. Renton, Richard J. Perrin, Sarah B. Berman, Jasmeer P. Chhatwal, Martin R. Farlow, Gregory S. Day, Takeshi Ikeuchi, Mathias Jucker, Francisco Lopera, Hiroshi Mori, James M. Noble, Raquel Sánchez-Valle, Peter R. Schofield, John C. Morris
Studies suggest distinct differences in the development, presentation, progression, and response to treatment of Alzheimer's disease (AD) between females and males. We investigated sex differences in cognition, neuroimaging, and fluid biomarkers in dominantly inherited AD (DIAD).
-
ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-23 Lavanya Jain, Maria Khrestian, Shane Formica, Elizabeth D. Tuason, Jagan A. Pillai, Stephen Rao, Odinachi Oguh, Carol F. Lippa, Oscar L. Lopez, Sarah B. Berman, Debby W. Tsuang, Cyrus P. Zabetian, David J. Irwin, Douglas R. Galasko, Irene Litvan, Karen S. Marder, Lawrence S. Honig, Jori E. Fleisher, James E. Galvin, Andrea C. Bozoki, Angela S. Taylor, Marwan N. Sabbagh, James B. Leverenz, Lynn M. Bekris
The National Institute on Aging – Alzheimer's Association (NIA-AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD pathological features and track changes longitudinally. The overall aim was to utilize this framework to characterize pre-mortem ATN status longitudinally in a clinically diagnosed cohort of dementia with
-
Sex differences in risk factors, burden, and outcomes of cerebrovascular disease in Alzheimer's disease populations Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-21 Cassandra Morrison, Mahsa Dadar, Donald Louis Collins
White matter hyperintensities (WMHs) are associated with cognitive decline and progression to mild cognitive impairment (MCI) and dementia. It remains unclear if sex differences influence WMH progression or the relationship between WMH and cognition.
-
Associations of cortical SPP1 and ITGAX with cognition and common neuropathologies in older adults Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-19 Katia de Paiva Lopes, Lei Yu, Xianli Shen, Yiguo Qiu, Shinya Tasaki, Artemis Iatrou, Michal Schnaider Beeri, Nicholas T. Seyfried, Vilas Menon, Yanling Wang, Julie A. Schneider, Harvey Cantor, David A. Bennett
The secreted phosphoprotein 1 (SPP1) gene expressed by CD11c+ cells is known to be associated with microglia activation and neuroinflammatory diseases. As most studies rely on mouse models, we investigated these genes and proteins in the cortical brain tissue of older adults and their role in Alzheimer's disease (AD) and related disorders.
-
Risk of cognitive decline progression is associated to increased blood-brain-barrier permeability: A longitudinal study in a memory unit clinical cohort Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-19 Albert Puig-Pijoan, Joan Jimenez-Balado, Aida Fernández-Lebrero, Greta García-Escobar, Irene Navalpotro-Gómez, Jose Contador, Rosa-María Manero-Borràs, Victor Puente-Periz, Antoni Suárez, Francisco J. Muñoz, Oriol Grau-Rivera, Marc Suárez-Calvet, Rafael de la Torre, Jaume Roquer, Angel Ois
This study examined the relationship between blood-brain-barrier permeability (BBBp), measured by cerebrospinal fluid/serum albumin ratio (QAlb), and cognitive decline progression in a clinical cohort.
-
Inadequate reimbursement for lumbar puncture is a potential barrier to accessing new Alzheimer's disease treatments Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-18 Samuele Bonomi, Mahendra R. Gupta, Suzanne E. Schindler
Alzheimer's disease (AD) is the most common cause of dementia1 and is characterized by the deposition of amyloid plaques and tau neurofibrillary tangles in the brain, which are thought to initiate a cascade leading to progressive neurodegeneration and cognitive impairment. The U.S. Food and Drug Administration (FDA) recently approved lecanemab after it was demonstrated to slow cognitive decline in
-
Health care utilization and costs in the years preceding dementia identification Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-18 Raj G. Kumar, Evan Bollens Lund, Katherine A. Ornstein, Jing Li, Kenneth E. Covinsky, Amy S. Kelley
There is evidence that health care utilization increases after incident dementia, particularly after dementia diagnosis and toward the end of life; however, less is known about utilization in the years before dementia identification.
-
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022 Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-12 Dallas P. Veitch, Michael W. Weiner, Melanie Miller, Paul S. Aisen, Miriam A. Ashford, Laurel A. Beckett, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, Susan M. Landau, John C. Morris, Kwangsik T. Nho, Rachel Nosheny, Ozioma Okonkwo, Richard J. Perrin, Ronald C. Petersen, Monica Rivera Mindt, Andrew Saykin, Leslie M. Shaw, Arthur W. Toga, Duygu Tosun
The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease
-
The intersection of social determinants of health and family care of people living with Alzheimer's disease and related dementias: A public health opportunity Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-12 Joseph E. Gaugler, Soo Borson, Fayron Epps, Regina A. Shih, Lauren J. Parker, Lisa C. McGuire
In this Perspective article, we highlight current research to illustrate the intersection of social determinants of health (SDOHs) and Alzheimer's disease and related dementia (ADRD) caregiving. We then outline how public health can support ADRD family caregivers in the United States. Emerging research suggests that family care for persons with ADRD is influenced by SDOHs. Public health actions that
-
The potential clinical value of plasma biomarkers in Alzheimer's disease Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-11 Kaj Blennow, Douglas Galasko, Robert Perneczky, Frances-Catherine Quevenco, Wiesje M. van der Flier, Akin Akinwonmi, Margherita Carboni, Alexander Jethwa, Ivonne Suridjan, Henrik Zetterberg
Many people with cognitive complaints or impairment never receive an accurate diagnosis of the underlying condition, potentially impacting their access to appropriate treatment. To address this unmet need, plasma biomarker tests are being developed for use in Alzheimer's disease (AD). Plasma biomarker tests span various stages of development, including in vitro diagnostic devices (or tests) (IVDs)
-
Delirium is associated with loss of feedback cortical connectivity Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-11 Klevest Gjini, Cameron Casey, David Kunkel, Maihlee Her, Matthew I. Banks, Robert A. Pearce, Richard Lennertz, Robert D. Sanders
Post-operative delirium (POD) is associated with increased morbidity and mortality but is bereft of treatments, largely due to our limited understanding of the underlying pathophysiology. We hypothesized that delirium reflects a disturbance in cortical connectivity that leads to altered predictions of the sensory environment.
-
Anesthesia-induced hippocampal-cortical hyperactivity and tau hyperphosphorylation impair remote memory retrieval in Alzheimer's disease Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-11 Kai Chen, Riya Gupta, Alejandro Martín-Ávila, Meng Cui, Zhongcong Xie, Guang Yang
Anesthesia often exacerbates memory recall difficulties in individuals with Alzheimer's disease (AD), but the underlying mechanisms remain unclear.
-
Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-10 Wiesje Pelkmans, Mahnaz Shekari, Anna Brugulat-Serrat, Gonzalo Sánchez-Benavides, Carolina Minguillón, Karine Fauria, Jose Luis Molinuevo, Oriol Grau-Rivera, Armand González Escalante, Gwendlyn Kollmorgen, Margherita Carboni, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Marc Suarez-Calvet, Juan Domingo Gispert
We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages.
-
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-10 Hanna Cho, Nidhi S. Mundada, Liana G. Apostolova, Maria C. Carrillo, Ranjani Shankar, Alinda N. Amuiri, Ehud Zeltzer, Charles C. Windon, David N. Soleimani-Meigooni, Jeremy A. Tanner, Courtney Lawhn Heath, Orit H. Lesman-Segev, Paul Aisen, Ani Eloyan, Hye Sun Lee, Dustin B. Hammers, Kala Kirby, Jeffrey L. Dage, Anne Fagan, Tatiana Foroud, Lea T. Grinberg, Clifford R. Jack, Joel Kramer, Walter A. Kukull
We aimed to describe baseline amyloid-beta (Aβ) and tau-positron emission tomograrphy (PET) from Longitudinal Early-onset Alzheimer's Disease Study (LEADS), a prospective multi-site observational study of sporadic early-onset Alzheimer's disease (EOAD).
-
Profiles of lifestyle health behaviors and cognitive decline in older adults Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-07 Shannon Halloway, Maude Wagner, Christy Tangney, Brittney S. Lange-Maia, David A. Bennett, Zoe Arvanitakis, Michael E. Schoeny
We aimed to identify profiles of modifiable, late-life lifestyle health behaviors related to subsequent maintenance of cognition and explore sociodemographics and health characteristics as effect modifiers.
-
Capillary dysfunction in healthy elderly APOE ε4 carriers with raised brain Aβ deposition Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-07 Lasse S. Madsen, Pernille L. Kjeldsen, Rola Ismail, Peter Parbo, Leif Østergaard, David J. Brooks, Simon F. Eskildsen
Capillary dysfunction, characterized by disturbances in capillary blood flow distribution, might be an overlooked factor in the development of Alzheimer's disease (AD). This study investigated microvascular blood flow in preclinical and prodromal AD individuals.
-
Association between metabolic syndrome and risk of incident dementia in UK Biobank Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-07 Danial Qureshi, Jennifer Collister, Naomi E. Allen, Elżbieta Kuźma, Thomas Littlejohns
The association between metabolic syndrome (MetS) and incident dementia remains inconclusive.
-
Plasma Alzheimer's biomarkers and brain amyloid in Hispanic and non-Hispanic older adults Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-06 Breton M. Asken, Wei-En Wang, Karen McFarland, Franchesca Arias, Jacob Fiala, Idaly Velez-Uribe, Robin P. Mayrand, Luana Okino Sawada, Christian Freytes, Michael Adeyosoye, Michael Marsiske, Monica Rosselli, Warren W. Barker, Rosie Curiel Cid, David A. Loewenstein, Steven T. DeKosky, Melissa J. Armstrong, Glenn E. Smith, Malek Adjouadi, David E. Vaillancourt, Ranjan Duara
Alzheimer's disease studies often lack ethnic diversity.
-
Identifying individuals with non-Alzheimer's disease co-pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-04 Duygu Tosun, Ozlem Yardibi, Tammie L. S. Benzinger, Walter A. Kukull, Colin L. Masters, Richard J. Perrin, Michael W. Weiner, Arthur Simen, Adam J. Schwarz
Biomarkers remain mostly unavailable for non-Alzheimer's disease neuropathological changes (non-ADNC) such as transactive response DNA-binding protein 43 (TDP-43) proteinopathy, Lewy body disease (LBD), and cerebral amyloid angiopathy (CAA).
-
Trajectories of cognitive and perceived functional decline in people with dementia: Findings from the IDEAL programme Alzheimers Dement. (IF 14.0) Pub Date : 2023-09-02 Anthony Martyr, Madhumathi Ravi, Laura D. Gamble, Robin G Morris, Jennifer M. Rusted, Claire Pentecost, Fiona E. Matthews, Linda Clare
Impaired cognition and instrumental activities of daily living (iADL) are key diagnostic features of dementia; however, few studies have compared trajectories of cognition and iADL.
-
Toward digitally screening and profiling AD: A GAMLSS approach of MemTrax in China Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-31 Wanwan Liu, Ling Yu, Qiuqiong Deng, Yunrong Li, Peiwen Lu, Jie Yang, Fei Chen, Feng Li, Xianbo Zhou, Michael F. Bergeron, John Wesson Ashford, Qun Xu
To establish a normative range of MemTrax (MTx) metrics in the Chinese population.
-
Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-31 Laura M. Winchester, Eric L. Harshfield, Liu Shi, AmanPreet Badhwar, Ahmad Al Khleifat, Natasha Clarke, Amir Dehsarvi, Imre Lengyel, Ilianna Lourida, Christopher R. Madan, Sarah J. Marzi, Petroula Proitsi, Anto P. Rajkumar, Timothy Rittman, Edina Silajdžić, Stefano Tamburin, Janice M. Ranson, David J. Llewellyn
With the increase in large multimodal cohorts and high-throughput technologies, the potential for discovering novel biomarkers is no longer limited by data set size. Artificial intelligence (AI) and machine learning approaches have been developed to detect novel biomarkers and interactions in complex data sets. We discuss exemplar uses and evaluate current applications and limitations of AI to discover
-
Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-31 Justin Bushnell, Dustin B. Hammers, Paul Aisen, Jeffrey L. Dage, Ani Eloyan, Tatiana Foroud, Lea T. Grinberg, Leonardo Iaccarino, Clifford R. Jack, Kala Kirby, Joel Kramer, Robert Koeppe, Walter A. Kukull, Renaud La Joie, Nidhi S. Mundada, Melissa E. Murray, Kelly Nudelman, Malia Rumbaugh, David N. Soleimani-Meigooni, Arthur Toga, Alexandra Touroutoglou, Prashanthi Vemuri, Alireza Atri, Gregory S.
The Rey Auditory Verbal Learning Test (RAVLT) is a useful neuropsychological test for describing episodic memory impairment in dementia. However, there is limited research on its utility in early-onset Alzheimer's disease (EOAD). We assess the influence of amyloid and diagnostic syndrome on several memory scores in EOAD.
-
Characterizing the emergence of amyloid and tau burden in Down syndrome Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-29 Matthew D. Zammit, Tobey J. Betthauser, Andrew K. McVea, Charles M. Laymon, Dana L. Tudorascu, Sterling C. Johnson, Sigan L. Hartley, Alexander K. Converse, Davneet S. Minhas, Shahid H. Zaman, Beau M. Ances, Charles K. Stone, Chester A. Mathis, Annie D. Cohen, William E. Klunk, Benjamin L. Handen, Bradley T. Christian
Almost all individuals with Down syndrome (DS) will develop neuropathological features of Alzheimer's disease (AD). Understanding AD biomarker trajectories is necessary for DS-specific clinical interventions and interpretation of drug-related changes in the disease trajectory.
-
AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-28 Sigan L. Hartley, Benjamin Handen, Dana Tudorascu, Laisze Lee, Annie Cohen, Emily K. Schworer, Jamie C. Peven, Matthew Zammit, William Klunk, Charles Laymon, Davneet Minhas, Weiquan Luo, Shahid Zaman, Beau Ances, Gregory Preboske, Bradley T. Christian
Down syndrome (DS) is a genetic cause of early-onset Alzheimer's disease (AD). The National Institute on Aging–Alzheimer's Association AT(N) Research Framework is a staging model for AD biomarkers but has not been assessed in DS.
-
Sex differences in the association between tau PET and cognitive performance in a non-Hispanic White cohort with preclinical AD Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-28 Xin Wang, Erin E. Sundermann, Rachel F. Buckley, Sarah J. Banks
We investigated how the associations between tau and cognitive measures differ by sex in the preclinical Alzheimer's disease (AD) stage.
-
Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-28 Rowan Saloner, Lawren VandeVrede, Breton M. Asken, Emily W. Paolillo, Eva Q. Gontrum, Amy Wolf, Argentina Lario-Lago, Marta Milà-Alomà, Gallen Triana-Baltzer, Hartmuth C. Kolb, Dena B. Dubal, Gil D. Rabinovici, Bruce L. Miller, Adam L. Boxer, Kaitlin B. Casaletto, Joel H. Kramer
Accumulating evidence indicates disproportionate tau burden and tau-related clinical progression in females. However, sex differences in plasma phosphorylated tau (p-tau)217 prediction of subclinical cognitive and brain changes are unknown.
-
Artificial intelligence for dementia research methods optimization Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-28 Magda Bucholc, Charlotte James, Ahmad Al Khleifat, AmanPreet Badhwar, Natasha Clarke, Amir Dehsarvi, Christopher R. Madan, Sarah J. Marzi, Cameron Shand, Brian M. Schilder, Stefano Tamburin, Hanz M. Tantiangco, , Ilianna Lourida, David J. Llewellyn, Janice M. Ranson
Artificial intelligence (AI) and machine learning (ML) approaches are increasingly being used in dementia research. However, several methodological challenges exist that may limit the insights we can obtain from high-dimensional data and our ability to translate these findings into improved patient outcomes. To improve reproducibility and replicability, researchers should make their well-documented
-
The heritability of blood-based biomarkers related to risk of Alzheimer's disease in a population-based sample of early old-age men Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-25 Nathan A. Gillespie, Jeremy A. Elman, Ruth E. McKenzie, Xin M. Tu, Hong Xian, Chandra A. Reynolds, Matthew S. Panizzon, Michael J. Lyons, Graham M. L. Eglit, Michael C. Neale, Robert A. Rissman, Carol Franz, William S. Kremen
Despite their increased application, the heritability of Alzheimer's disease (AD)–related blood-based biomarkers remains unexplored.
-
Primary retinal tauopathy: A tauopathy with a distinct molecular pattern Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-24 Grzegorz Walkiewicz, Alicja Ronisz, Rita Van Ginderdeuren, Sophie Lemmens, Femke H. Bouwman, Jeroen J. M. Hoozemans, Tjado H. J. Morrema, Annemieke J. Rozemuller, Frederique J. Hart de Ruyter, Lies De Groef, Ingeborg Stalmans, Dietmar Rudolf Thal
Phosphorylated tau (p-tau) accumulation, a hallmark of Alzheimer's disease (AD), can also be found in the retina. However, it is uncertain whether it is linked to AD or another tauopathy.
-
Successful cognitive aging is associated with thicker anterior cingulate cortex and lower tau deposition compared to typical aging Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-24 Stefania Pezzoli, Joseph Giorgio, Adam Martersteck, Lindsey Dobyns, Theresa M. Harrison, William J. Jagust
There is no consensus on either the definition of successful cognitive aging (SA) or the underlying neural mechanisms.
-
Mapping sleep's oscillatory events as a biomarker of Alzheimer's disease Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-23 Rachelle L. Pulver, Eugene Kronberg, Lindsey M. Medenblik, Vitaly O. Kheyfets, Alberto R. Ramos, David M. Holtzman, John C. Morris, Cristina D. Toedebusch, Stefan H Sillau, Brianne M. Bettcher, Brendan P. Lucey, Brice V. McConnell
Memory-associated neural circuits produce oscillatory events including theta bursts (TBs), sleep spindles (SPs), and slow waves (SWs) in sleep electroencephalography (EEG). Changes in the “coupling” of these events may indicate early Alzheimer's disease (AD) pathogenesis.
-
Thinner inner retinal layers are associated with lower cognitive performance, lower brain volume, and altered white matter network structure—The Maastricht Study Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-23 Frank C. T. van der Heide, Indra L. M. Steens, Betsie Limmen, Sara Mokhtar, Martin P. J. van Boxtel, Miranda T. Schram, Sebastian Köhler, Abraham A. Kroon, Carla J. H. van der Kallen, Pieter C. Dagnelie, Martien C. J. M. van Dongen, Simone J. P. M. Eussen, Tos T. J. M. Berendschot, Carroll A. B. Webers, Marleen M. J. van Greevenbroek, Annemarie Koster, Thomas T. van Sloten, Jacobus F. A. Jansen, Walter
The retina may provide non-invasive, scalable biomarkers for monitoring cerebral neurodegeneration.
-
Artificial intelligence for dementia genetics and omics Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-22 Conceicao Bettencourt, Nathan Skene, Sara Bandres-Ciga, Emma Anderson, Laura M. Winchester, Isabelle F. Foote, Jeremy Schwartzentruber, Juan A. Botia, Mike Nalls, Andrew Singleton, Brian M. Schilder, Jack Humphrey, Sarah J. Marzi, Christina E. Toomey, Ahmad Al Kleifat, Eric L. Harshfield, Victoria Garfield, Cynthia Sandor, Samuel Keat, Stefano Tamburin, Carlo Sala Frigerio, Ilianna Lourida, , Janice
Genetics and omics studies of Alzheimer's disease and other dementia subtypes enhance our understanding of underlying mechanisms and pathways that can be targeted. We identified key remaining challenges: First, can we enhance genetic studies to address missing heritability? Can we identify reproducible omics signatures that differentiate between dementia subtypes? Can high-dimensional omics data identify
-
Correction to “A new LC-MS/MS assay for the quantification of Aβ40 and Aβ42 in plasma: Validation and clinical performance” Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-21
The AAIC 2022 abstract by Weber DM, Kim JC, Goldman S, et al. A new LC-MS/MS assay for the quantification of Aβ40 and Aβ42 in plasma: Validation and clinical performance. Alzheimers Dement. 2022;18(S6):E064182. doi:10.1002/alz.064182, contains an error. Sensitivity and specificity estimates were inadvertently switched. The text in the results section should read: “At the Aβ42/40 cut-point of 0.160
-
Evaluation of the NIH Toolbox Odor Identification Test across normal cognition, amnestic mild cognitive impairment, and dementia due to Alzheimer's disease Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-21 Shiloh L. Echevarria-Cooper, Emily H. Ho, Richard C. Gershon, Sandra Weintraub, Thorsten Kahnt
Olfactory decline is associated with cognitive decline in aging, amnestic mild cognitive impairment (aMCI), and amnestic dementia associated with Alzheimer's disease neuropathology (ADd). The National Institutes of Health Toolbox Odor Identification Test (NIHTB-OIT) may distinguish between these clinical categories.
-
Where are caregivers in the clinical trial? Evaluation of caregiver responsibilities in Alzheimer's disease and related dementias clinical trials Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-18 Armando Miranda, Eve Rubovits, Raksha Mudar, Vania Leung, Minakshi Raj
Family caregivers of persons with Alzheimer's disease and related dementias (ADRD) have significant responsibilities within health care. They may identify relevant clinical trials and support decision-making about their relative's participation. The objectives of this study were to (a) evaluate the responsibilities of caregivers related to their relative's participation in ADRD clinical trials and
-
Different cohort, disparate results: Selection bias is a key factor in autopsy cohorts Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-17 Kathryn Gauthreaux, Walter A. Kukull, Karin B. Nelson, Charles Mock, Yen-Chi Chen, Kwun C. G. Chan, David W. Fardo, Yuriko Katsumata, Erin L. Abner, Peter T. Nelson
Research-oriented autopsy cohorts provide critical insights into dementia pathobiology. However, different studies sometimes report disparate findings, partially because each study has its own recruitment biases. We hypothesized that a straightforward metric, related to the percentage of research volunteers cognitively normal at recruitment, would predict other inter-cohort differences.
-
Risk factors for dementia in older intensive care unit (ICU) survivors Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-17 Sophia Wang, Anthony J. Perkins, Rosalyn Chi, Brandon A. Yates, Sikandar H. Khan, Sujuan Gao, Malaz Boustani, Babar A. Khan
As the number of older intensive care unit (ICU) survivors grows, there is an urgent need to identify modifiable risk factors for post-ICU dementia.
-
Antidepressants and the risk of bleeding in the era of anti-amyloid drugs Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-16 Beatriz Pozuelo Moyano, Paolo Salvioni, Leonardo Zullo, Olivier Rouaud, Armin von Gunten, François R. Girardin, Gilles Allali
Dear Editor, The prevalence of depression ranges from 19% to 78% in dementia, and apathy and depression are the most frequent behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD).1 Antidepressant annual prescription prevalence among AD patients is ≈ 28%.2They are approved in depressive and anxiety disorders and are an effective treatment for mood and anxiety disorders
-
Artificial intelligence for dementia drug discovery and trials optimization Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-16 Thomas Doherty, Zhi Yao, Ahmad A.l. Khleifat, Hanz Tantiangco, Stefano Tamburin, Chris Albertyn, Lokendra Thakur, David J. Llewellyn, Neil P. Oxtoby, Ilianna Lourida, , Janice M. Ranson, James A. Duce
Drug discovery and clinical trial design for dementia have historically been challenging. In part these challenges have arisen from patient heterogeneity, length of disease course, and the tractability of a target for the brain. Applying big data analytics and machine learning tools for drug discovery and utilizing them to inform successful clinical trial design has the potential to accelerate progress
-
AI-based assessments of speech and language impairments in dementia Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-14 Mahboobeh Parsapoor
Recent advancements in the artificial intelligence (AI) domain have revolutionized the early detection of cognitive impairments associated with dementia. This has motivated clinicians to use AI-powered dementia detection systems, particularly systems developed based on individuals' and patients' speech and language, for a quick and accurate identification of patients with dementia. This paper reviews
-
Systematic review and meta-analysis on population attributable fraction for physical inactivity to dementia Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-14 Natan Feter, Jayne S. Leite, Luísa Silveira da Silva, Júlia Cassuriaga, Danilo de Paula, Gabriela Wünsch Lopes, Pedro Rodrigues Curi Hallal, I-Min Lee, Airton José Rombaldi
The number of cases of dementia attributable to physical inactivity remains unclear due to heterogeneity in physical inactivity definitions and statistical approaches used.
-
DNA from multiple viral species is associated with Alzheimer's disease risk Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-14 Marlene Tejeda, John Farrell, Congcong Zhu, Lee Wetzler, Kathryn L. Lunetta, William S. Bush, Eden R. Martin, Li-San Wang, Gerard D. Schellenberg, Margaret A. Pericak-Vance, Jonathan L. Haines, Lindsay A. Farrer, Richard Sherva
Multiple infectious agents, including viruses, bacteria, fungi, and protozoa, have been linked to Alzheimer's disease (AD) risk by independent lines of evidence. We explored this association by comparing the frequencies of viral species identified in a large sample of AD cases and controls.
-
White matter hyperintensity longitudinal morphometric analysis in association with Alzheimer disease Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-10 Jeremy Fuller Strain, Chia-Ling Phuah, Babatunde Adeyemo, Kathleen Cheng, Kyle B. Womack, John McCarthy, Manu Goyal, Yasheng Chen, Aristeidis Sotiras, Hongyu An, Chengjie Xiong, Andrea Scharf, Catherine Newsom-Stewart, John Carl Morris, Tammie Lee Smith Benzinger, Jin-Moo Lee, Beau M. Ances
Vascular damage in Alzheimer's disease (AD) has shown conflicting findings particularly when analyzing longitudinal data. We introduce white matter hyperintensity (WMH) longitudinal morphometric analysis (WLMA) that quantifies WMH expansion as the distance from lesion voxels to a region of interest boundary.
-
Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-10 Robin J. Borchert, Tiago Azevedo, AmanPreet Badhwar, Jose Bernal, Matthew Betts, Rose Bruffaerts, Michael C. Burkhart, Ilse Dewachter, Helena M. Gellersen, Audrey Low, Ilianna Lourida, Luiza Machado, Christopher R. Madan, Maura Malpetti, Jhony Mejia, Sofia Michopoulou, Carlos Muñoz-Neira, Jack Pepys, Marion Peres, Veronica Phillips, Siddharth Ramanan, Stefano Tamburin, Hanz M. Tantiangco, Lokendra
Artificial intelligence (AI) and neuroimaging offer new opportunities for diagnosis and prognosis of dementia.
-
Association of type 2 diabetes mellitus with dementia-related and non–dementia-related mortality among postmenopausal women: A secondary competing risks analysis of the women's health initiative Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-10 Tyler J. Titcomb, Phyllis Richey, Ramon Casanova, Lawrence S. Phillips, Simin Liu, Shama D. Karanth, Nazmus Saquib, Tomas Nuño, JoAnn E. Manson, Aladdin H. Shadyab, Longjian Liu, Terry L. Wahls, Linda G. Snetselaar, Robert B. Wallace, Wei Bao
Alzheimer's disease (AD) and AD-related dementias (ADRD) are leading causes of death among older adults in the United States. Efforts to understand risk factors for prevention are needed.
-
Transcriptional risk scores in Alzheimer's disease: From pathology to cognition Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-10 Jung-Min Pyun, Young Ho Park, Jiebiao Wang, David A. Bennett, Paula J. Bice, Jun Pyo Kim, SangYun Kim, Andrew J. Saykin, Kwangsik Nho
Our previously developed blood-based transcriptional risk scores (TRS) showed associations with diagnosis and neuroimaging biomarkers for Alzheimer's disease (AD). Here, we developed brain-based TRS.
-
The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-09 Cecilia Boccalini, Federica Ribaldi, Ines Hristovska, Annachiara Arnone, Débora Elisa Peretti, Linjing Mu, Max Scheffler, Daniela Perani, Giovanni B. Frisoni, Valentina Garibotto
Tau and neurodegeneration strongly correlate with cognitive impairment, as compared to amyloid. However, their contribution in explaining cognition and predicting cognitive decline in memory clinics remains unclarified.
-
Associations of inner retinal layers with risk of incident dementia: An individual participant data analysis of four prospective cohort studies Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-08 Frank C. T. van der Heide, Anthony Khawaja, Tos T. J. M. Berendschot, Thomas J. Littlejohns, Elżbieta Kuźma, Robert Luben, Praveen J. Patel, Paul J. Foster, , Geir Bertelsen, Therese von Hanno, Bente Johnsen, Henrik Schirmer, Sara C. L. Rebouças, Leslie Grasset, Cécile Delcourt, Catherine Helmer, , , Coen D. A. Stehouwer
Our main objective was to investigate whether retinal neurodegeneration, estimated from lower thickness of inner retinal layers, was associated with incident all-cause dementia and Alzheimer's disease (AD).
-
Cardiovascular health, infection burden, and incident dementia in the UK Biobank Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-07 Hind A. Beydoun, May A. Beydoun, Osorio Meirelles, Lance D. Erickson, Alyssa A. Gamaldo, Jordan Weiss, Lenore J. Launer, Michele K. Evans, Alan B. Zonderman
Among older adults, total and hospitalized infection may be associated with incidence of all-cause and Alzheimer's disease (AD) dementias, with variation by cardiovascular health (CVH).
-
Symptom-led staging for semantic and non-fluent/agrammatic variants of primary progressive aphasia Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-07 Chris J. D. Hardy, Cathleen Taylor-Rubin, Beatrice Taylor, Emma Harding, Aida Suarez Gonzalez, Jessica Jiang, Laura Thompson, Rachel Kingma, Anthipa Chokesuwattanaskul, Ffion Walker, Suzie Barker, Emilie Brotherhood, Claire Waddington, Olivia Wood, Nikki Zimmermann, Nuriye Kupeli, Keir X. X. Yong, Paul M. Camic, Joshua Stott, Charles R. Marshall, Neil P. Oxtoby, Jonathan D. Rohrer, Anna Volkmer, Sebastian
Here we set out to create a symptom-led staging system for the canonical semantic and non-fluent/agrammatic variants of primary progressive aphasia (PPA), which present unique diagnostic and management challenges not well captured by functional scales developed for Alzheimer's disease and other dementias.
-
Therapeutic strategies in vascular cognitive impairment: A systematic review of population, intervention, comparators, and outcomes Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-04 Federico Masserini, Giacomo Baso, Claudia Gendarini, Leonardo Pantoni
Vascular cognitive impairment (VCI) is a common and heterogeneous condition, clinically and pathophysiologically, that still lacks approved treatment.
-
Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-03 Pamela C. L. Ferreira, Joseph Therriault, Cécile Tissot, João Pedro Ferrari-Souza, Andréa L. Benedet, Guilherme Povala, Bruna Bellaver, Douglas T. Leffa, Wagner S. Brum, Firoza Z. Lussier, Gleb Bezgin, Stijn Servaes, Marie Vermeiren, Arthur C. Macedo, Arlec Cabrera, Jenna Stevenson, Gallen Triana-Baltzer, Hartmuth Kolb, Nesrine Rahmouni, William E. Klunk, Oscar L. Lopez, Victor L. Villemagne, Ann Cohen
Phosphorylated tau (p-tau) biomarkers have been recently proposed to represent brain amyloid-β (Aβ) pathology. Here, we evaluated the plasma biomarkers' contribution beyond the information provided by demographics (age and sex) to identify Aβ and tau pathologies in individuals segregated as cognitively unimpaired (CU) and impaired (CI).
-
Effect of exercise engagement and cardiovascular risk on neuronal injury Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-03 Marta Stojanovic, Suzanne E. Schindler, John C. Morris, Denise Head
Neuronal health as a potential underlying mechanism of the beneficial effects of exercise has been understudied in humans. Furthermore, there has been limited consideration of potential moderators (e.g., cardiovascular health) on the effects of exercise.
-
Cardiovascular health and cognitive outcomes: Findings from a biracial population-based study in the United States Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-03 Anisa Dhana, Charles S. DeCarli, Klodian Dhana, Pankaja Desai, Thomas M. Holland, Denis A. Evans, Kumar B. Rajan
The aim of this study was to evaluate the association of cardiovascular health (CVH) with cognitive outcomes, including incident Alzheimer's dementia, rate of cognitive decline, and measures of brain injury and structure.
-
The scope of using pragmatic language tests for early detection of dementia: A systematic review of investigations using figurative language Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-03 Madhushree Chakrabarty, Nathaniel Klooster, Atanu Biswas, Anjan Chatterjee
Dementia cases are expected to rise to 81.1 million in 2040. Efforts are underway to develop diagnostic methods to facilitate early detection of the disease. Herein we review research findings focusing on pragmatic dysfunction in patients with dementia and evaluate the usefulness of assessing dementia and its progress with a battery of tests assessing figurative language skills.
-
Skeletal muscle mitochondrial function predicts cognitive impairment and is associated with biomarkers of Alzheimer's disease and neurodegeneration Alzheimers Dement. (IF 14.0) Pub Date : 2023-08-02 Qu Tian, Murat Bilgel, Keenan A. Walker, Abhay R. Moghekar, Kenneth W. Fishbein, Richard G. Spencer, Susan M. Resnick, Luigi Ferrucci
Mitochondrial dysfunction is implicated in the pathophysiology of many chronic diseases. Whether it is related to cognitive impairment and pathological markers is unknown.
-
Advancing specificity in delirium: The delirium subtyping initiative Alzheimers Dement. (IF 14.0) Pub Date : 2023-07-31 Emily M. L. Bowman, Nathan E. Brummel, Gideon A. Caplan, Colm Cunningham, Lis A. Evered, Kirsten M. Fiest, Timothy D. Girard, Thomas A. Jackson, Sara C. LaHue, Heidi L. Lindroth, Alasdair M. J. Maclullich, Daniel F. McAuley, Esther S. Oh, Mark A. Oldham, Valerie J. Page, Pratik P. Pandharipande, Kelly M. Potter, Pratik Sinha, Arjen J. C. Slooter, Aoife M. Sweeney, Zoë Tieges, Edwin Van Dellen, Mary
Delirium, a common syndrome with heterogeneous etiologies and clinical presentations, is associated with poor long-term outcomes. Recording and analyzing all delirium equally could be hindering the field's understanding of pathophysiology and identification of targeted treatments. Current delirium subtyping methods reflect clinically evident features but likely do not account for underlying biology